<?xml version="1.0" encoding="UTF-8"?>
<p>Following common standard operating procedures and previously published PCR/RT-PCR conditions[
 <xref rid="pone.0233117.ref009" ref-type="bibr">9</xref>â€“
 <xref rid="pone.0233117.ref012" ref-type="bibr">12</xref>], NP swabs were examined for molecular evidence of influenza A and B virus (IAV, IBV)[
 <xref rid="pone.0233117.ref009" ref-type="bibr">9</xref>], adenovirus[
 <xref rid="pone.0233117.ref010" ref-type="bibr">10</xref>], enterovirus (EV)[
 <xref rid="pone.0233117.ref011" ref-type="bibr">11</xref>], and coronavirus (CoV)[
 <xref rid="pone.0233117.ref012" ref-type="bibr">12</xref>]. Primer and probe sequences for targeted pathogens are recorded in 
 <xref ref-type="supplementary-material" rid="pone.0233117.s002">S1 Table</xref>. A positive and a no-template control were included in each run. Coronavirus-positive samples were sent to Bio Basic Asia Pacific Pte. Ltd. (Singapore) for Sanger sequencing.
</p>
